Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement

Inclusion Criteria:

1. Patients with histologically confirmed diagnosis of advanced malignancy and liver involvement as dominant site of metastasis.
2. Performance status ECOG \< or = 2 (Requires occasional assistance but is able to care for own needs).
3. Adequate renal function (serum creatinine \< 2.0 mg/dL).
4. Adequate hepatic function (Total bilirubin \< 2.0 mg/dL; ALT \</= 5 times upper normal reference value).
5. Bone marrow function (ANC \>or =1.5 cells/mcL; PLT \> or = 100,000 cells/mcL).
6. At least three weeks from previous therapy and complete recovery from all associated acute toxicities.
7. Ability to fully read, comprehend, and sign informed consent forms.
8. All females in childbearing age must have a negative urine or serum HCG test unless prior hysterectomy or menopause. Women of childbearing potential and men must use effective birth control.
9. Patients should be refractory to standard chemotherapy or have no conventional therapy that produces a CR rate of at least 10% or an increase in survival of at least three months.
10. Patients of both genders, 13 year-old or older.

Exclusion Criteria:

1. Clinical or radiographic evidence of ascites.
2. Pregnant or breastfeeding females.
3. Hypersensitivity to paclitaxel compounds.
4. History of severe hypersensitivity reactions to products containing polyoxyethylated castor oil or Cremophor.
5. Inability to complete informed consent process and adhere to protocol treatment plan and follow-up requirements.
6. Untreatable bleeding diathesis.
7. Portal vein thrombosis.
8. Peripheral neuropathy \> Grade 1 according to NCI CTC v.3.0: sensory alteration not interfering with function).
9. Untreated (radiation therapy, chemotherapy, surgery or a combination of modalities) brain metastasis.